Literature DB >> 17459275

The spectrum of prostate cancer care: from curative intent to palliation.

Ased S M Ali1, Freddie C Hamdy.   

Abstract

Prostate cancer is one of the most prevalent malignancies affecting men in the developed world. A spectrum of disease states exists and management is tailored to individual patients. Increasing public awareness and prostate-specific antigen testing have led to earlier detection and the possibility of cure but have increased the risk of overtreatment of indolent disease. Advances in curative modalities have reduced side effects and offer patients a choice of treatments. Nonetheless, many need no intervention and may be safely treated with active monitoring. Choice and timing of therapy for locally advanced and recurrent disease are variable, with potential benefits of early intervention counterbalanced by side effects of treatment. Progress has been made in the management of advanced disease; skeletal-related events have been reduced and survival has been increased. This review examines the evidence and rationale behind the treatment options from curative intent to management of locally advanced disease and palliation of metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459275     DOI: 10.1007/s11934-007-0013-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  47 in total

1.  An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.

Authors:  Frank A Vicini; Alvaro Martinez; Gerald Hanks; Alex Hanlon; Brian Miles; Ken Kernan; David Beyers; Haakon Ragde; Jeffrey Forman; James Fontanesi; Larry Kestin; Gyorgy Kovacs; Louis Denis; Kevin Slawin; Peter Scardino
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

Review 2.  Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.

Authors:  Charles J Ryan; Eric J Small
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

3.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

4.  Impotence following radical prostatectomy: insight into etiology and prevention.

Authors:  P C Walsh; P J Donker
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

5.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

Authors: 
Journal:  Br J Urol       Date:  1997-02

6.  Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

Authors:  D P Byar; D K Corle
Journal:  NCI Monogr       Date:  1988

7.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

Review 8.  Markers and meaning of primary treatment failure.

Authors:  Peter W Swindle; Michael W Kattan; Peter T Scardino
Journal:  Urol Clin North Am       Date:  2003-05       Impact factor: 2.241

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Authors:  G O N Oosterhof; J T Roberts; Th M de Reijke; S A Engelholm; S Horenblas; H von der Maase; N Neymark; M Debois; L Collette
Journal:  Eur Urol       Date:  2003-11       Impact factor: 20.096

View more
  2 in total

1.  Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: a promising approach for the treatment of prostate cancer.

Authors:  Juliana M Sousa-Canavez; Flavio C Canavez; Kátia R M Leite; Luiz H Camara-Lopes
Journal:  Genet Vaccines Ther       Date:  2008-01-18

2.  The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.

Authors:  Antonio Cassio Assis Pellizzon; João Salvajoli; Paulo Novaes; Maria Maia; Ricardo Fogaroli; Doglas Gides; Rodrigues Horriot
Journal:  Int J Med Sci       Date:  2008-06-04       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.